<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837069</url>
  </required_header>
  <id_info>
    <org_study_id>12-02407</org_study_id>
    <nct_id>NCT01837069</nct_id>
  </id_info>
  <brief_title>Risk Factor Control Before Orthopedic Surgery</brief_title>
  <acronym>OPTMIZE-OS</acronym>
  <official_title>Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to determine the best preoperative management strategy for patients
      undergoing orthopedic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OPTIMIZE - OS (Optimization of Pre-surgical Testing with an Intensive Multifactorial
      Intervention to MinimiZe Cardiovascular Events - Orthopedic Surgery) trial is to determine
      the best management strategy for patients undergoing orthopedic surgery. OPTIMIZE will be a
      prospective randomized trial that will enroll patients during pre-surgical testing before
      orthopedic surgery. This trial will investigate different strategies aimed at lowering
      cardiovascular events following orthopedic surgery. The study will compare an intensive
      multifactorial intervention comprising behavioral modification and polypharmacologic therapy
      aimed at several modifiable risk factors versus usual care. The trial hypothesis is that a
      personalized optimization approach is superior to usual care in reducing a composite of
      death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous
      thromboembolism or thrombosis requiring reoperation at 30-days. Secondary endpoints include
      length of stay, major bleeding, each individual endpoint from the primary endpoint, and
      quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment / DSMB approval to halt recruitment
  </why_stopped>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Composite of Cardiovascular Events</measure>
    <time_frame>30 days</time_frame>
    <description>the reduction in the composite of death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous thromboembolism, or reoperation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Hospital stay, ~7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Each Individual Endpoint of the Composite of Cardiovascular Events</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>25mg PO BID if the HR is elevated at preadmission testing</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Beta blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>2.5mg PO QD if the HR is elevated at preadmission testing</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>ACE inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80mg PO QD at preadmission testing</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle counseling</intervention_name>
    <description>Diet, exercise, medication adherance and smoking counseling</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • ≥ 21 years of age

               -  Subjects undergoing open orthopedic surgery of the hip, knee or spine

               -  Surgery is scheduled at least 3 days after PAT visit and no more than 14 days.

               -  High risk subject cohort

                    -  Coronary artery disease, or

                    -  Cerebrovascular disease (prior stroke, TIA or carotid artery disease (&gt;70%
                       stenosis), or

                    -  Peripheral artery disease, or

                    -  Prior Venous thromboembolism or arterial thromboembolism, or

                    -  Age ≥ 60 years and 2 of the following

               -  Renal insufficiency (creatinine clearance &lt; 60ml/min)

               -  Diabetes

               -  COPD

               -  Hypertension

               -  Active smoker or stopped less than 30 days prior to consent

               -  Cancer (excluding BCC)

               -  Heart Failure

        Exclusion Criteria:

          -  • Known intolerance to statins

               -  Subject is already on maximum dose statin (atorvastatin/Lipitor 80mg daily or
                  rosuvastatin/crestor 40mg daily)

               -  Bilateral renal artery stenosis

               -  End stage renal disease (receiving dialysis or CrCl &lt;30ml/min)

               -  Known allergy or intolerance to ACE-inhibitor (other than cough) or Angiotensin
                  receptor blocker (e.g. angioedema, hyperkalemia)

               -  Known allergy or intolerance to beta blockers

               -  Known sick sinus syndrome not treated with permanent pacemaker

               -  Known greater than first degree AV block not treated with a pacemaker

               -  Excessive alcohol intake

               -  Acute Coronary Syndrome requiring hospitalization within 1 month

               -  Stroke within 1 month

               -  Known pregnancy

               -  Severe co-morbid condition with life expectancy &lt; 6 months

               -  Inability to give informed consent or adhere to follow-up as per protocol

               -  Current participation in another investigational drug or device trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Hospital for Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>July 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2020</results_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01837069/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Standard of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Standard of care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># Unknown or not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Composite of Cardiovascular Events</title>
        <description>the reduction in the composite of death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous thromboembolism, or reoperation</description>
        <time_frame>30 days</time_frame>
        <population>No data are available for this Outcome Measure. Multiple efforts were made to obtain the data from the PI but were unsuccessful, therefore, data cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Composite of Cardiovascular Events</title>
          <description>the reduction in the composite of death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous thromboembolism, or reoperation</description>
          <population>No data are available for this Outcome Measure. Multiple efforts were made to obtain the data from the PI but were unsuccessful, therefore, data cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Length of Stay</title>
        <time_frame>Hospital stay, ~7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Each Individual Endpoint of the Composite of Cardiovascular Events</title>
        <time_frame>30 days</time_frame>
        <population>Efforts were made to collect this data from PI, but data analysis was not completed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Each Individual Endpoint of the Composite of Cardiovascular Events</title>
          <population>Efforts were made to collect this data from PI, but data analysis was not completed for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
Metoprolol: 25mg PO BID if the HR is elevated at preadmission testing
Lisinopril: 2.5mg PO QD if the HR is elevated at preadmission testing
Atorvastatin: 80mg PO QD at preadmission testing
Lifestyle counseling: Diet, exercise, medication adherance and smoking counseling</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Standard of care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Berger</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212 263 4004</phone>
      <email>Jeffrey.Berger@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

